Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 381,421 shares of the biopharmaceutical company's stock after selling 61,158 shares during the quarter. Teacher Retirement System of Texas' holdings in Gilead Sciences were worth $42,738,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Redwood Financial Network Corp lifted its position in Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 98 shares in the last quarter. Nicolet Advisory Services LLC lifted its stake in Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after purchasing an additional 100 shares during the last quarter. Peak Financial Advisors LLC raised its stake in Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after buying an additional 100 shares in the last quarter. Perkins Coie Trust Co grew its holdings in shares of Gilead Sciences by 2.6% during the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after buying an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. raised its position in shares of Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on GILD shares. Bank of America boosted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Oppenheimer reduced their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Wells Fargo & Company upped their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Trading Down 0.2%

Shares of NASDAQ GILD traded down $0.24 during midday trading on Thursday, hitting $111.28. 4,039,811 shares of the company traded hands, compared to its average volume of 7,692,289. Gilead Sciences, Inc. has a 12-month low of $66.01 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The stock has a 50-day moving average price of $106.75 and a 200 day moving average price of $103.67. The firm has a market cap of $138.42 billion, a P/E ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same period in the prior year, the company earned ($1.32) earnings per share. The firm's revenue was down .3% on a year-over-year basis. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer owned 615,725 shares of the company's stock, valued at $68,006,826.25. This represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the sale, the insider owned 120,168 shares in the company, valued at $13,238,908.56. The trade was a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,500 shares of company stock worth $6,340,745. Company insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.